myasthenia

IMAAVY (nipocalimab)shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)

Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including…

2 weeks ago

Vitaccess and Myasthenia Gravis Foundation of America form strategic partnership to advance generation of real-world evidence in MG

Vitaccess and Myasthenia Gravis Foundation of America form strategic partnership to advance generation of real-world evidence in MG Boston, MA,…

3 months ago

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

September 07, 2025 18:25 ET  | Source: Dianthus Therapeutics, Inc. NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE)…

8 months ago